Slight positive. Upgrades margins slightly.
• Sales $2,822m +5% CC. Slightly ahead of consensus
• Guidance mid-single digit sales growth is unchanged. Margin 21-22% from ~21%.
• Quarterly growth Q1 3%; Q2 5%; Q3 6%
• Biosimilars grew 17% at the company’s acquisition adjusted rate.
• Biosimilars represented 31% of total in Q3 driven by acquisition of Cimerli.
• Large pipeline of assets ready to take advantage of $220bn patent expiration.
• N America 22%; Intl 24%; Europe 54%
Find more articles and bullets on these widgets:
Brent futures traded higher last week, however, the contract has pulled back from its recent peak. A resumption of gains would suggest scope for a continuation of a bullish corrective cycle and expose key resistance at $71.93, the Jul 30 high. The medium-term outlook appears bearish and sights are on key support and the bear trigger at $64.50, the Jun 30 low. Clearance of this level would strengthen a bearish theme.
RBA Governor Bullock said that monetary policy is “a bit restrictive” but the bank doesn’t know how restrictive it is but it’s neither “very restrictive” nor expansionary. Therefore, decisions will be made on a meeting-by-meeting basis and will be highly data and outlook dependent. She stated that it is “good news” that activity is picking up but the Board will watch what this means for inflation and employment going forward.